Real World Predictors, Timing, and Outcomes of Autologous Stem Cell Transplantation in Patients with Multiple Myeloma
Background—Autologous stem cell transplant (ASCT) is integral to the treatment of multiple myeloma (MM), although its absolute necessity in first remission has been recently questioned. We report real-world factors that influence clinical decision-making and outcomes from ASCT in 733 patients with M...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Hemato |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-6357/5/4/30 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846104433804443648 |
|---|---|
| author | Lisa Blackburn Anthony Mansour Qiuhong Zhao Francesca Cottini Abdullah Khan Naresh Bumma Srinivas Devarakonda Elvira Umyarova Ashley E. Rosko Jennifer Vaughn Nidhi Sharma Don M. Benson |
| author_facet | Lisa Blackburn Anthony Mansour Qiuhong Zhao Francesca Cottini Abdullah Khan Naresh Bumma Srinivas Devarakonda Elvira Umyarova Ashley E. Rosko Jennifer Vaughn Nidhi Sharma Don M. Benson |
| author_sort | Lisa Blackburn |
| collection | DOAJ |
| description | Background—Autologous stem cell transplant (ASCT) is integral to the treatment of multiple myeloma (MM), although its absolute necessity in first remission has been recently questioned. We report real-world factors that influence clinical decision-making and outcomes from ASCT in 733 patients with MM. Results—Similar to recent prospective data, we found a significant progression-free survival (PFS) benefit with early versus deferred ASCT (median PFS of 5.1 years versus 2.6 years, <i>p</i> < 0.001); however, there was no significant difference in overall survival (median OS of 8.3 years and 8.6 years, <i>p</i> = 0.21). Patient preference, age, marital status, body mass index, and comorbidities influence ASCT timing. Conclusion—These findings highlight the emerging role of an individualized, shared decision-making model regarding the timing of ASCT between patients and physicians with the myriad of treatment options available in the contemporary era. |
| format | Article |
| id | doaj-art-74fea70754cd49ecb2ce6793d2d86f15 |
| institution | Kabale University |
| issn | 2673-6357 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Hemato |
| spelling | doaj-art-74fea70754cd49ecb2ce6793d2d86f152024-12-27T14:28:38ZengMDPI AGHemato2673-63572024-10-015440741910.3390/hemato5040030Real World Predictors, Timing, and Outcomes of Autologous Stem Cell Transplantation in Patients with Multiple MyelomaLisa Blackburn0Anthony Mansour1Qiuhong Zhao2Francesca Cottini3Abdullah Khan4Naresh Bumma5Srinivas Devarakonda6Elvira Umyarova7Ashley E. Rosko8Jennifer Vaughn9Nidhi Sharma10Don M. Benson11Division of Hematology, Department of Internal Medicine, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center, 308 Wiseman Hall, 400 W. 10th Avenue, Columbus, OH 43210, USADivision of Hematology, Department of Internal Medicine, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center, 308 Wiseman Hall, 400 W. 10th Avenue, Columbus, OH 43210, USADivision of Hematology, Department of Internal Medicine, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center, 308 Wiseman Hall, 400 W. 10th Avenue, Columbus, OH 43210, USADivision of Hematology, Department of Internal Medicine, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center, 308 Wiseman Hall, 400 W. 10th Avenue, Columbus, OH 43210, USADivision of Hematology, Department of Internal Medicine, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center, 308 Wiseman Hall, 400 W. 10th Avenue, Columbus, OH 43210, USADivision of Hematology, Department of Internal Medicine, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center, 308 Wiseman Hall, 400 W. 10th Avenue, Columbus, OH 43210, USADivision of Hematology, Department of Internal Medicine, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center, 308 Wiseman Hall, 400 W. 10th Avenue, Columbus, OH 43210, USADivision of Hematology, Department of Internal Medicine, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center, 308 Wiseman Hall, 400 W. 10th Avenue, Columbus, OH 43210, USADivision of Hematology, Department of Internal Medicine, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center, 308 Wiseman Hall, 400 W. 10th Avenue, Columbus, OH 43210, USADivision of Hematology, Department of Internal Medicine, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center, 308 Wiseman Hall, 400 W. 10th Avenue, Columbus, OH 43210, USADivision of Hematology, Department of Internal Medicine, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center, 308 Wiseman Hall, 400 W. 10th Avenue, Columbus, OH 43210, USADivision of Hematology, Department of Internal Medicine, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center, 308 Wiseman Hall, 400 W. 10th Avenue, Columbus, OH 43210, USABackground—Autologous stem cell transplant (ASCT) is integral to the treatment of multiple myeloma (MM), although its absolute necessity in first remission has been recently questioned. We report real-world factors that influence clinical decision-making and outcomes from ASCT in 733 patients with MM. Results—Similar to recent prospective data, we found a significant progression-free survival (PFS) benefit with early versus deferred ASCT (median PFS of 5.1 years versus 2.6 years, <i>p</i> < 0.001); however, there was no significant difference in overall survival (median OS of 8.3 years and 8.6 years, <i>p</i> = 0.21). Patient preference, age, marital status, body mass index, and comorbidities influence ASCT timing. Conclusion—These findings highlight the emerging role of an individualized, shared decision-making model regarding the timing of ASCT between patients and physicians with the myriad of treatment options available in the contemporary era.https://www.mdpi.com/2673-6357/5/4/30myelomaearly transplantdeferred transplantoutcomesdecision-making |
| spellingShingle | Lisa Blackburn Anthony Mansour Qiuhong Zhao Francesca Cottini Abdullah Khan Naresh Bumma Srinivas Devarakonda Elvira Umyarova Ashley E. Rosko Jennifer Vaughn Nidhi Sharma Don M. Benson Real World Predictors, Timing, and Outcomes of Autologous Stem Cell Transplantation in Patients with Multiple Myeloma Hemato myeloma early transplant deferred transplant outcomes decision-making |
| title | Real World Predictors, Timing, and Outcomes of Autologous Stem Cell Transplantation in Patients with Multiple Myeloma |
| title_full | Real World Predictors, Timing, and Outcomes of Autologous Stem Cell Transplantation in Patients with Multiple Myeloma |
| title_fullStr | Real World Predictors, Timing, and Outcomes of Autologous Stem Cell Transplantation in Patients with Multiple Myeloma |
| title_full_unstemmed | Real World Predictors, Timing, and Outcomes of Autologous Stem Cell Transplantation in Patients with Multiple Myeloma |
| title_short | Real World Predictors, Timing, and Outcomes of Autologous Stem Cell Transplantation in Patients with Multiple Myeloma |
| title_sort | real world predictors timing and outcomes of autologous stem cell transplantation in patients with multiple myeloma |
| topic | myeloma early transplant deferred transplant outcomes decision-making |
| url | https://www.mdpi.com/2673-6357/5/4/30 |
| work_keys_str_mv | AT lisablackburn realworldpredictorstimingandoutcomesofautologousstemcelltransplantationinpatientswithmultiplemyeloma AT anthonymansour realworldpredictorstimingandoutcomesofautologousstemcelltransplantationinpatientswithmultiplemyeloma AT qiuhongzhao realworldpredictorstimingandoutcomesofautologousstemcelltransplantationinpatientswithmultiplemyeloma AT francescacottini realworldpredictorstimingandoutcomesofautologousstemcelltransplantationinpatientswithmultiplemyeloma AT abdullahkhan realworldpredictorstimingandoutcomesofautologousstemcelltransplantationinpatientswithmultiplemyeloma AT nareshbumma realworldpredictorstimingandoutcomesofautologousstemcelltransplantationinpatientswithmultiplemyeloma AT srinivasdevarakonda realworldpredictorstimingandoutcomesofautologousstemcelltransplantationinpatientswithmultiplemyeloma AT elviraumyarova realworldpredictorstimingandoutcomesofautologousstemcelltransplantationinpatientswithmultiplemyeloma AT ashleyerosko realworldpredictorstimingandoutcomesofautologousstemcelltransplantationinpatientswithmultiplemyeloma AT jennifervaughn realworldpredictorstimingandoutcomesofautologousstemcelltransplantationinpatientswithmultiplemyeloma AT nidhisharma realworldpredictorstimingandoutcomesofautologousstemcelltransplantationinpatientswithmultiplemyeloma AT donmbenson realworldpredictorstimingandoutcomesofautologousstemcelltransplantationinpatientswithmultiplemyeloma |